Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Ltd (SOLARA) is scheduled to report results on 16 Oct 2026. Solara Active Pharma Sciences Ltd last reported results for the quarter ended Jun 2026, with sales of ₹382 crore and net profit of ₹16 crore. The stock last traded at ₹683, a market capitalisation of ₹3,315 crore, on a P/E of 776. Over the past 52 weeks the stock has ranged between ₹422 and ₹774. Figures are as of 6 Oct 2026 and are not real time.
Solara Active Pharma Sciences Ltd share price and key metrics
- Current price
- ₹683
- Market cap
- ₹3,315 cr
- Stock P/E
- 776
- Book value
- ₹346
- ROE
- -0.13%
- ROCE
- 4.86%
- Dividend yield
- 0.00%
- 52w high / low
- 774/422
Metrics as of 6 Oct 2026. Not real time.
Track Solara Active Pharma Sciences Ltd
Cruxal reads every Solara Active Pharma Sciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Solara Active Pharma Sciences Ltd growth and returns
- 10 Years
- %
- 5 Years
- -3%
- 3 Years
- -2%
- TTM
- 15%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 25%
- TTM
- -83%
- 10 Years
- %
- 5 Years
- -13%
- 3 Years
- 28%
- 1 Year
- 11%
- 10 Years
- %
- 5 Years
- -7%
- 3 Years
- -12%
- Last Year
- 0%
Solara Active Pharma Sciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹382 cr, up 19.7% from ₹319 cr a year earlier. Net profit was ₹16 cr, up 45.5% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 347 | 300 | 273 | 319 | 314 | 349 | 387 | 382 |
| Expenses | 286 | 243 | 228 | 262 | 279 | 312 | 330 | 320 |
| Operating profit | 61 | 58 | 45 | 57 | 35 | 37 | 58 | 62 |
| OPM % | 18% | 19% | 17% | 18% | 11% | 11% | 15% | 16% |
| Other income | 0 | 1 | 6 | 1 | 0 | -7 | 6 | 3 |
| Interest | 28 | 27 | 29 | 24 | 21 | 22 | 28 | 22 |
| Depreciation | 25 | 25 | 24 | 24 | 24 | 26 | 26 | 27 |
| Profit before tax | 8 | 8 | -2 | 11 | -10 | -17 | 10 | 16 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net profit | 8 | 8 | -2 | 11 | -10 | -17 | 10 | 16 |
| EPS (₹) | 2.22 | 2.24 | -0.58 | 2.91 | -2.79 | -4.82 | 2.65 | 3.38 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Solara Active Pharma Sciences Ltd annual results
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 521 | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,289 | 1,284 | 1,369 | 1,431 |
| Operating profit | 57 | 213 | 260 | 386 | 81 | 134 | -95 | 206 | 187 | 192 |
| OPM % | 11% | 15% | 20% | 24% | 6% | 9% | -7% | 16% | 14% | 13% |
| Net profit | 0 | 59 | 115 | 221 | -58 | -22 | -567 | 1 | -7 | -2 |
| EPS (₹) | — | 17.30 | 32.01 | 46.22 | -12.11 | -4.62 | -118.21 | 0.15 | -2.05 | -1.58 |
TTM is the trailing twelve months to the most recent quarter.
Solara Active Pharma Sciences Ltd balance sheet
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 25 | 26 | 27 | 36 | 36 | 36 | 36 | 40 | 45 |
| Reserves | 739 | 930 | 1,059 | 1,553 | 1,489 | 1,464 | 898 | 1,054 | 1,208 |
| Borrowings | 633 | 538 | 722 | 621 | 1,037 | 1,013 | 1,012 | 796 | 687 |
| Other liabilities | 425 | 466 | 346 | 404 | 383 | 386 | 406 | 342 | 393 |
| Total liabilities | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 | 2,333 |
| Fixed assets | 1,086 | 1,218 | 1,397 | 1,382 | 1,356 | 1,364 | 1,268 | 1,193 | 1,238 |
| CWIP | 71 | 40 | 40 | 88 | 239 | 238 | 256 | 280 | 205 |
| Investments | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 5 |
| Other assets | 663 | 701 | 716 | 1,144 | 1,350 | 1,295 | 825 | 757 | 886 |
| Total assets | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 | 2,333 |
As reported by the company. Total assets equal total liabilities by construction.
Solara Active Pharma Sciences Ltd cash flow
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 49 | 166 | 242 | 155 | -242 | 156 | 109 | 213 | 153 |
| Cash from investing | -85 | -113 | -359 | -106 | -243 | -81 | -4 | -37 | -99 |
| Cash from financing | 68 | -23 | 97 | 92 | 334 | -113 | -106 | -180 | -54 |
| Net cash flow | 31 | 30 | -20 | 142 | -151 | -38 | -0 | -4 | 1 |
| Free cash flow | 14 | 108 | -25 | -16 | -451 | 46 | 69 | 173 | 101 |
| CFO / operating profit | 92% | 85% | 103% | 49% | -277% | 106% | -113% | 104% | 83% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Solara Active Pharma Sciences Ltd operating ratios
| Per year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| ROCE % | — | 10% | 12% | 15% | -0% | 2% | -9% | 6% | 5% |
| Debtor days | 184 | 76 | 63 | 109 | 141 | 136 | 99 | 93 | 117 |
| Inventory days | 252 | 111 | 170 | 149 | 321 | 258 | 163 | 185 | 170 |
| Days payable | 420 | 127 | 132 | 156 | 154 | 142 | 142 | 144 | 146 |
| Cash conversion cycle | 16 | 60 | 101 | 102 | 308 | 252 | 120 | 134 | 140 |
| Working capital days | -124 | -22 | -32 | 16 | 37 | 20 | -128 | -62 | -24 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Solara Active Pharma Sciences Ltd shareholding pattern
Promoters held 41.93% at Jun 2026, broadly unchanged since Jun 2025. FIIs 11.52% and DIIs 3.74%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 37.27% | 37.23% | 37.94% | 42.01% | 42.01% | 42.00% | 42.00% | 41.93% |
| FIIs | 14.25% | 14.67% | 14.63% | 14.25% | 13.58% | 11.98% | 11.59% | 11.52% |
| DIIs | 3.37% | 3.19% | 2.61% | 2.62% | 2.69% | 3.64% | 3.75% | 3.74% |
| Public | 45.11% | 44.92% | 44.82% | 41.10% | 41.71% | 42.37% | 42.66% | 42.79% |
| No. of shareholders | 71,882 | 83,148 | 75,791 | 74,334 | 72,479 | 71,890 | 70,400 | 70,490 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Solara Active Pharma Sciences Ltd’s next results date?
Solara Active Pharma Sciences Ltd’s next results are scheduled for 16 Oct 2026.
- Board meetingApproval of unaudited financial results for Q2 and H1 FY2027
See the full results calendar for every Indian company reporting in the next 30 days.
Solara Active Pharma Sciences Ltd corporate filings
- Solara Active Pharma Sciences Approves Final Reminder and Forfeiture Notice for Outstanding Rights Issue PaymentsCompany Updatelow impact
Cruxal's analysis: Solara Active Pharma Sciences Limited has announced the approval of a final reminder and…
Read the full analysis - Solara Active Pharma Sciences schedules Board Meeting to consider Q2 FY2027 unaudited financial resultsBoard Meetinghigh impact
Cruxal's analysis: Solara Active Pharma Sciences has announced a Board meeting scheduled for October 16…
Read the full analysis - Solara Active Pharma Sciences Limited has informed the Exchange about Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended ....Company Updatelow impact
- Solara Active Pharma Sciences Ltd issues mandatory notice for PAN, KYC, and nomination updates for physical shareholdersCompany Updatelow impact
Cruxal's analysis: Solara Active Pharma Sciences has issued a routine regulatory intimation requiring…
Read the full analysis - Intimation regarding Closure of Trading window for the quarter ended September 30, 2026Insider Trading / SASTlow impact
- Solara Active Pharma Sciences Limited secures shareholder approval for 480 crore INR related party transactions with Strides Pharma Science LimitedAGM/EGMlow impact
Cruxal's analysis: Solara Active Pharma Sciences Limited has successfully concluded its Ninth Annual General…
Read the full analysis - Solara Active Pharma Sciences Limited concludes Ninth AGM; shareholders approve material related party transactions up to INR 480 croreAGM/EGMlow impact
Cruxal's analysis: Solara Active Pharma Sciences Limited successfully held its Ninth Annual General Meeting…
Read the full analysis - Solara Active Pharma Sciences Limited secures rectification order, dropping INR 161.92 crore tax demandCompany Updatehigh impact
Cruxal's analysis: Solara Active Pharma Sciences Limited has successfully resolved a significant tax dispute…
Read the full analysis - Solara Active Pharma Sciences Limited Announces Ninth Annual General Meeting (AGM) to be Held via Video ConferencingCompany Updatelow impact
Cruxal's analysis: Solara Active Pharma Sciences Limited has issued a formal intimation regarding the…
Read the full analysis - Solara Active Pharma Sciences Ltd announces Business Responsibility and Sustainability Reporting (BRSR) for FY 2025-26Otherslow impact
Cruxal's analysis: Solara Active Pharma Sciences has filed its Business Responsibility and Sustainability…
Read the full analysis - Solara Active Pharma Sciences Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Solara Active Pharma Sciences Ltd has filed its Annual Report for the financial year…
Read the full analysis - Solara Active Pharma Sciences Limited Announces Ninth AGM and Seeks Approval for Material Related Party Transactions with Strides Pharma Science LimitedAGM/EGMmedium impact
Cruxal's analysis: Solara Active Pharma Sciences Limited has scheduled its Ninth Annual General Meeting for…
Read the full analysis - Solara Active Pharma Sciences Limited announces newspaper publication for Ninth Annual General MeetingCompany Updatelow impact
Cruxal's analysis: Solara Active Pharma Sciences Limited has fulfilled regulatory requirements under…
Read the full analysis - Solara Active Pharma Sciences converts 2.80 lakh partly paid-up shares into fully paid-up equityCompany Updatelow impact
Cruxal's analysis: Solara Active Pharma Sciences Limited has approved the conversion of 2,79,582 partly…
Read the full analysis - Solara Active Pharma Sciences Ltd allots 2,250 equity shares under ESOPCompany Updatelow impact
Cruxal's analysis: Solara Active Pharma Sciences Limited has announced the allotment of 2,250 equity shares…
Read the full analysis - Solara Active Pharma Sciences Limited announces minor delay in joining date for new Chief Information OfficerCompany Updatelow impact
Cruxal's analysis: Solara Active Pharma Sciences Limited has issued a routine disclosure regarding a change…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.